Beta%2525252525252525252525252525252525252525252520blockers

## Beta Blockers ### Overview Beta-adrenergic blocking agents (beta blockers) competitively inhibit the binding of catecholamines (epinephrine and norepinephrine) to beta-adrenergic receptors (beta-1 and beta-2). This results in decreased heart rate, myocardial contractility, and blood pressure. Some beta blockers also have intrinsic sympathomimetic activity (ISA) or alpha-blocking activity. ### Primary Indications * Hypertension * Angina Pectoris * Myocardial Infarction (post-MI management) * Heart Failure (specific agents) * Arrhythmias (e.g., supraventricular tachycardia, atrial fibrillation rate control) * Migraine Prophylaxis * Essential Tremor * Glaucoma (topical) * Anxiety (situational symptom management) ### Adult Dosing Dosing is highly drug-specific and varies by indication. Titration is typically required. * **Hypertension:** Many beta blockers are used. Common starting doses (may be titrated upwards): * Metoprolol tartrate: 25-50 mg twice daily * Metoprolol succinate: 25-50 mg once daily * Atenolol: 25-50 mg once daily * Propranolol: 20-40 mg twice daily * Carvedilol: 3.125 mg twice daily * Labetalol: 100 mg twice daily * Nebivolol: 5 mg once daily * **Post-MI:** Generally initiated within 24 hours if no contraindications. * Metoprolol tartrate: 50 mg every 6 hours, then titrate to 100 mg twice daily. * **Heart Failure (HFrEF):** Specific agents (e.g., carvedilol, metoprolol succinate, bisoprolol) are initiated at low doses and *slowly* titrated. Consult specific guidelines for target doses. * Carvedilol: Start 3.125 mg twice daily, titrate slowly to target. * Metoprolol succinate: Start 12.5-25 mg once daily, titrate slowly to target. * Bisoprolol: Start 2.5 mg once daily, titrate slowly to target. * **Rate Control (e.g., Atrial Fibrillation):** * Metoprolol tartrate: 25-50 mg IVP every 5 minutes as needed (max 15 mg) or 25-50 mg PO q6h. * Propranolol: 10-30 mg PO q6-8h. * **Migraine Prophylaxis:** * Propranolol: 40-80 mg twice daily. * Metoprolol tartrate: 50-100 mg twice daily. * **Essential Tremor:** * Propranolol: 40 mg twice daily, may increase to 120 mg twice daily. * **Anxiety (Situational):** * Propranolol: 10-40 mg 1 hour prior to event. *Note: Specific dosing protocols, especially for titrated therapies like heart failure or post-MI, may vary based on local institutional guidelines.* ### Pediatric Dosing Pediatric dosing is less established and often based on weight and specific indication. Consultation with a pediatric specialist or pharmacist is recommended. * Generally, pediatric dosing is approximately 1/3 to 1/2 of adult doses initially, then titrated. * For hypertension, typical starting doses (weight-based): * Propranolol: 0.5-1 mg/kg/day divided into 2-3 doses. * Atenolol: 0.5-1 mg/kg/day once daily. * For supraventricular tachycardia prophylaxis/rate control: * Propranolol: 1-5 mg/kg/day divided into 3-4 doses. ### Dose Adjustments * **Hepatic Impairment:** Dose reduction may be necessary for hepatically metabolized beta blockers (e.g., propranolol, metoprolol, carvedilol). Labetalol and atenolol generally require less adjustment. * **Renal Impairment:** Dose reduction may be necessary for renally cleared beta blockers (e.g., atenolol). Metoprolol and propranolol generally require less adjustment unless severe impairment. ### Contraindications * Severe bradycardia * High-degree atrioventricular (AV) block (second or third degree) without a pacemaker * Cardiogenic shock * Uncompensated heart failure * Sick sinus syndrome * Known hypersensitivity to the specific beta blocker * Severe peripheral arterial disease * Asthma or COPD (relative contraindication, particularly for non-selective beta blockers unless benefits clearly outweigh risks and a cardioselective agent is chosen cautiously). * Pheochromocytoma (must be managed with an alpha-blocker first). ### Adverse Effects Common adverse effects are dose-related and include: * Bradycardia * Hypotension * Fatigue, dizziness, drowsiness * Cold extremities * Nausea, vomiting, diarrhea * Bronchospasm (especially non-selective agents) * Masking of hypoglycemia symptoms (except sweating) in diabetics * Erectile dysfunction * Depression * Hallucinations (rare) * Aggravation of psoriasis ### Key Drug Interactions * **Other Antihypertensives (e.g., Diuretics, ACE inhibitors, ARBs, Calcium Channel Blockers):** Additive hypotensive effects. Increased risk of bradycardia and AV block with non-dihydropyridine calcium channel blockers (verapamil, diltiazem). * **Antiarrhythmics (e.g., Amiodarone, Flecainide):** Increased risk of bradycardia, AV block, and myocardial depression. * **Insulin and Oral Hypoglycemics:** Beta-blockers can mask tachycardia associated with hypoglycemia. * **CYP450 Enzyme Inducers/Inhibitors:** Can affect levels of metabolized beta blockers (e.g., propranolol, metoprolol). Examples: * Inducers (e.g., rifampin): May decrease beta blocker levels. * Inhibitors (e.g., fluoxetine, paroxetine, quinidine): May increase beta blocker levels. * **Digoxin:** Additive effect on slowing AV conduction. * **MAO Inhibitors:** Can cause hypertensive crisis; discontinue MAOI at least 14 days before starting beta blocker. ### Monitoring * Blood pressure and heart rate * Electrolytes (especially when used with diuretics) * Renal and hepatic function * Glucose levels (in diabetic patients) * Signs and symptoms of heart failure exacerbation * Signs of peripheral circulation impairment * Pulmonary status (especially in patients with respiratory disease) ### Clinical Pearls * Initiate at low doses and titrate slowly, especially in heart failure, elderly patients, or those with underlying cardiac conditions. * Abrupt discontinuation can lead to rebound hypertension, angina, or myocardial infarction. Taper dose over 1-2 weeks. * Cardioselective (beta-1 selective) agents (e.g., metoprolol, atenolol, bisoprolol, nebivolol) are generally preferred in patients with mild reactive airway disease, but caution is still advised. Non-selective agents (e.g., propranolol, nadolol) should be avoided in significant asthma/COPD. Labetalol and carvedilol have both alpha and beta blocking activity. * Beta blockers are less effective in controlling blood pressure in Black patients compared to other populations, but they remain an important part of therapy, often in combination with other agents. * In patients with pheochromocytoma, an alpha-blocker must be initiated first to prevent unopposed alpha-stimulation leading to hypertensive crisis. --- ***Disclaimer:*** *This information is intended for healthcare professionals and is not a substitute for detailed prescribing information. Always consult the most current drug manufacturer's prescribing information and relevant clinical guidelines before making any treatment decisions.*